Idhifa

Approved Indications

Idhifa is used to treat a specific type of blood and bone marrow cancer called acute myeloid leukemia (AML). It is prescribed for adults in the following situations:

• Relapsed AML: The cancer has returned after a period of improvement or remission.
• Refractory AML: The cancer did not respond to previous treatments.

Genetic Testing Requirements

This medication is a targeted therapy. It is only effective for patients whose leukemia cells have a specific mutation in the isocitrate dehydrogenase-2 (IDH2) gene. Before starting Idhifa, a healthcare provider must confirm the presence of this mutation using a specialized, FDA-approved diagnostic test.

Targeting the IDH2 Mutation

Idhifa is designed for people with acute myeloid leukemia (AML) who have a specific genetic mutation in the isocitrate dehydrogenase-2 (IDH2) enzyme. In a healthy body, this enzyme helps cells produce energy. However, when the enzyme is mutated, it causes the body to produce too much of a substance called 2-hydroxyglutarate (2-HG).

Restoring Cell Maturity

High levels of 2-HG interfere with the normal development of blood cells. Instead of maturing into functional white blood cells that fight infection, the cells remain in an immature state known as blasts. These blasts multiply quickly and crowd out healthy blood cells in the bone marrow and blood.

Idhifa works by:

• Blocking the mutated enzyme: The medication attaches to the mutated IDH2 enzyme to stop it from working.
• Reducing 2-HG levels: By blocking the enzyme, Idhifa lowers the amount of 2-HG in the body.
• Promoting differentiation: Once 2-HG levels drop, the immature leukemia cells are able to go through a process called differentiation, where they mature into normal, working blood cells.

Because Idhifa helps cells mature rather than simply killing them immediately, it is considered a type of differentiation therapy.

Common Side Effects

The most frequent side effects reported by people taking Idhifa include:

• Nausea and vomiting
• Diarrhea
• Decreased appetite
• Fatigue or weakness
• Changes in taste
• Increased bilirubin levels in the blood, which may cause yellowing of the skin or eyes (jaundice)

Serious Side Effects

Idhifa can cause severe complications that may require urgent medical care. These include:

• Differentiation Syndrome: This is a potentially life-threatening condition caused by the rapid maturation of leukemia cells. Symptoms include fever, cough, shortness of breath, sudden weight gain, and swelling in the arms, legs, or neck.
• Tumor Lysis Syndrome: This occurs when cancer cells die quickly and release their contents into the blood, which can lead to kidney damage or heart rhythm problems.
• High White Blood Cell Count: Also known as leukocytosis, this can occur during treatment and may require additional medication.
• Liver Issues: Elevated liver enzymes or worsening jaundice may occur.

Seek medical help right away if you notice signs of differentiation syndrome, such as difficulty breathing or rapid swelling, as this condition can be fatal if not treated promptly.

Differentiation Syndrome

Idhifa can cause a condition known as differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition occurs when leukemia cells release inflammatory chemicals into the blood. Symptoms can appear as early as 10 days or as late as five months after starting treatment. Healthcare providers monitor for signs such as:

• Fever and cough
• Difficulty breathing
• Rapid weight gain
• Swelling in the arms or legs
• Fluid buildup around the lungs or heart
• Low blood pressure

If differentiation syndrome is suspected, treatment typically involves high-dose corticosteroids and may require hospitalization or a temporary pause in Idhifa therapy.

Blood and Liver Monitoring

Regular blood tests are necessary during treatment to monitor for several potential complications:

• Leukocytosis: This medication can cause a significant increase in white blood cell counts. If levels become too high, additional medications may be needed to lower them.
• Elevated Bilirubin: Many patients experience increased levels of bilirubin in the blood. While often related to the drug's mechanism, healthcare providers must monitor liver function to ensure there is no underlying organ damage.
• Tumor Lysis Syndrome: The rapid breakdown of cancer cells can cause a release of waste products into the bloodstream, which may lead to kidney failure or heart rhythm problems.

Pregnancy and Reproductive Risks

Idhifa may cause harm to an unborn baby if taken during pregnancy. The following precautions are generally advised:

• Females of reproductive potential should use effective contraception during treatment and for at least one month after the final dose.
• Males with female partners who can become pregnant should use effective contraception during treatment and for at least one month after the final dose.
• Breastfeeding is not recommended during treatment and for at least one month after the last dose due to potential risks to the infant.

Pregnancy

Based on animal studies and its mechanism of action, Idhifa can cause harm to a fetus when taken during pregnancy. There are no adequate studies in humans to determine the specific risks, but the medication has shown embryo-fetal toxicity in animal research. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits with their healthcare provider.

Contraception

Healthcare providers typically recommend the following for patients of reproductive potential:

• Females: Use effective contraception during treatment and for at least one month after the final dose.
• Males: Use effective contraception (such as condoms) during treatment and for at least one month after the final dose if their partner is of reproductive potential.

Breastfeeding

It is currently unknown whether Idhifa passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least one month after the last dose.

Dosage Forms

Idhifa is supplied as a film-coated tablet intended for oral use. It is typically taken once daily.

The tablets should be swallowed whole. Do not chew, crush, or split the tablets before swallowing.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Idhifa in August 2017. It was the first oral targeted therapy approved for adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation known as isocitrate dehydrogenase-2 (IDH2). The drug was approved alongside a companion diagnostic test, the RealTime IDH2 Assay, which is used to identify patients who carry this specific mutation.

Boxed Warning

The prescribing information for Idhifa includes a Boxed Warning, the FDA's most serious warning, regarding the risk of differentiation syndrome. This condition is a serious and potentially fatal complication that occurs when leukemia cells mature too quickly. Symptoms of differentiation syndrome may include:

• Fever
• Cough or difficulty breathing
• Rapid weight gain
• Swelling in the arms or legs
• Fluid buildup around the lungs or heart

Regulatory Safety Communications

In 2018, the FDA issued a safety communication to alert healthcare professionals and patients that symptoms of differentiation syndrome were not always being recognized. The agency emphasized that if this condition is suspected, patients should be treated immediately with high-dose corticosteroids and monitored closely until their symptoms resolve. The FDA also updated the drug's prescribing information to include more detailed instructions on managing this risk.

Factors Influencing Cost

The total cost of Idhifa can vary based on your treatment plan, insurance coverage, and the pharmacy you use. Because Idhifa is a brand-name medication without a generic equivalent, the price is generally higher than older or off-patent treatments.

Insurance Coverage

Most insurance providers require prior authorization for Idhifa. This means your doctor must submit a request to your insurance company to confirm that the drug is medically necessary before the insurer will agree to cover the cost. Your out-of-pocket expenses, such as deductibles and co-pays, will depend on your specific plan.

Specialty Pharmacies

Idhifa is often distributed through specialty pharmacies. These pharmacies focus on medications for complex conditions like leukemia and may offer specialized services to help you manage your prescription and understand your insurance benefits.

Financial Assistance

Patients who have difficulty affording Idhifa may be eligible for support programs. These can include manufacturer-sponsored assistance for those with commercial insurance or programs for individuals who are uninsured. Additionally, some independent foundations provide grants to help cover the costs of cancer medications.